KRAS and neoplasm: The result of ESTIMATE revealed the stromal score, immune score, and ESTIMATE score were inferior, while the purity was higher in the KRAS-mutated group, suggesting a lower overall immune level and immunogenicity of the tumor microenvironment in the KRAS-mutated group (Figure 3A–3D).